drugs firm pierre dollar obesity several trade particularly hit confident europe success difficult however last continuing conditions results price treatments way anti bn known pence forward new pace generics absorbed depressants diabetes pipeline years aids means clinical important global business london failure good key terms jean disappointing cancer aims deliver company progress high copies discontinued growth allergies lost still hiv treatment fall also recovery glaxo depression relying early paxil experimental drug profits trial chief sales saw drugmaker mr grow said says wellbutrin weak profit look managing garnier products lift glaxosmithkline development performance executive cheap biggest afternoon despite share research year